Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Current Investments (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Cash & Current Investments for 8 consecutive years, with $650.9 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Current Investments rose 40.54% year-over-year to $650.9 million; the TTM value through Mar 2026 reached $650.9 million, up 40.54%, while the annual FY2025 figure was $848.3 million, 73.56% up from the prior year.
  • Cash & Current Investments hit $650.9 million in Q1 2026 for Kymera Therapeutics, down from $848.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $848.3 million in Q4 2025 and bottomed at $33.7 million in Q1 2022.
  • Average Cash & Current Investments over 5 years is $452.9 million, with a median of $481.9 million recorded in 2022.
  • Year-over-year, Cash & Current Investments plummeted 89.89% in 2022 and then skyrocketed 1076.52% in 2023.
  • Kymera Therapeutics' Cash & Current Investments stood at $407.2 million in 2022, then decreased by 7.93% to $374.9 million in 2023, then surged by 30.37% to $488.7 million in 2024, then soared by 73.56% to $848.3 million in 2025, then fell by 23.26% to $650.9 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $650.9 million, $848.3 million, and $505.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.